133 related articles for article (PubMed ID: 35421820)
1. Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER-medicare study.
Epstein RS; Nelms J; Moran D; Girman C; Huang H; Chioda M
Cancer Treat Res Commun; 2022; 31():100555. PubMed ID: 35421820
[TBL] [Abstract][Full Text] [Related]
2. Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers.
Epstein RS; Weerasinghe RK; Parrish AS; Krenitsky J; Sanborn RE; Salimi T
J Med Econ; 2022; 25(1):108-118. PubMed ID: 34927520
[TBL] [Abstract][Full Text] [Related]
3. Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study from community oncology practices.
Hart L; Ogbonnaya A; Boykin K; Deyoung K; Bailey R; Heritage T; Lopez-Gonzalez L; Huang H; Gordan L
Cancer Med; 2023 Apr; 12(8):10020-10030. PubMed ID: 37000119
[TBL] [Abstract][Full Text] [Related]
4. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
Ferrarotto R; Anderson I; Medgyasszay B; García-Campelo MR; Edenfield W; Feinstein TM; Johnson JM; Kalmadi S; Lammers PE; Sanchez-Hernandez A; Pritchett Y; Morris SR; Malik RK; Csőszi T
Cancer Med; 2021 Sep; 10(17):5748-5756. PubMed ID: 34405547
[TBL] [Abstract][Full Text] [Related]
5. Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings.
Goldschmidt J; Monnette A; Shi P; Venkatasetty D; Lopez-Gonzalez L; Huang H
Future Oncol; 2022 Nov; 18(35):3881-3894. PubMed ID: 36377828
[TBL] [Abstract][Full Text] [Related]
6. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
[No Abstract] [Full Text] [Related]
7. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
Griffiths RI; Barron RL; Gleeson ML; Danese MD; O'Hagan A; Chia VM; Legg JC; Lyman GH
Pharmacoeconomics; 2012 Feb; 30(2):103-18. PubMed ID: 21967155
[TBL] [Abstract][Full Text] [Related]
8. New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.
Balducci L; Falandry C; List A
Curr Oncol Rep; 2022 Dec; 24(12):1695-1703. PubMed ID: 35986858
[TBL] [Abstract][Full Text] [Related]
9. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
Thatcher N; Clark PI; Smith DB; Anderson H; Girling DJ; Machin D; Stephens RJ; Lallemand G; Jenkins B
Clin Oncol (R Coll Radiol); 1995; 7(5):293-9. PubMed ID: 8580054
[TBL] [Abstract][Full Text] [Related]
10. Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.
Stephens JM; Bensink M; Bowers C; Hollenbeak CS
Curr Med Res Opin; 2019 Feb; 35(2):229-240. PubMed ID: 29661043
[TBL] [Abstract][Full Text] [Related]
11. Survival, Chemotherapy Treatments, and Health Care Utilization Among Patients with Advanced Small Cell Lung Cancer: An Observational Study.
He J; Shao C; Hui SL; Zhang Z; Baker J; Dexter PR; Kachroo S; Jin F
Adv Ther; 2020 Jan; 37(1):552-565. PubMed ID: 31828610
[TBL] [Abstract][Full Text] [Related]
12. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
13. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
14. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.
Nichols CR; Fox EP; Roth BJ; Williams SD; Loehrer PJ; Einhorn LH
J Clin Oncol; 1994 Jun; 12(6):1245-50. PubMed ID: 7515413
[TBL] [Abstract][Full Text] [Related]
15. Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database.
Sosa R; Li S; Molony JT; Liu J; Stryker S; Collins AJ
Support Care Cancer; 2017 Oct; 25(10):3123-3132. PubMed ID: 28456908
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
17. Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019.
Wang CY; Heldermon CD; Vouri SM; Park H; Wheeler SE; Ramnaraign BH; Dang NH; Brown JD
JAMA Netw Open; 2021 Nov; 4(11):e2133474. PubMed ID: 34812849
[TBL] [Abstract][Full Text] [Related]
18. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.
Schenfeld J; Gong T; Henry D; Kelsh M; Gawade P; Peng Y; Bradbury BD; Li S
Support Care Cancer; 2022 Jul; 30(7):6327-6338. PubMed ID: 35482126
[TBL] [Abstract][Full Text] [Related]
19. Effects of chemotherapy on survival of elderly patients with small-cell lung cancer: analysis of the SEER-medicare database.
Caprario LC; Kent DM; Strauss GM
J Thorac Oncol; 2013 Oct; 8(10):1272-81. PubMed ID: 24457238
[TBL] [Abstract][Full Text] [Related]
20. Travel burden associated with granulocyte colony-stimulating factor administration in a Medicare aged population: a geospatial analysis.
Stephens JM; Bensink M; Bowers C; Hollenbeak CS
Curr Med Res Opin; 2018 Aug; 34(8):1351-1360. PubMed ID: 28722536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
